FDA Advisors Endorse Rexulti for Agitation in Alzheimer’s Dementia
FDA advisors voted in favor of brexpiprazole (Rexulti) for treating agitation associated with Alzheimer’s dementia (AAD), despite increased mortality risk. By a vote of 9-1 on Friday, members of the agency’s Psychopharmacologic Drugs Advisory Committee (PDAC) and the Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) said the data presented by the drug’s sponsors, […]